Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor‑resistant gastroesophageal reflux disease

Shinozaki,Satoshi; Osawa,Hiroyuki; Hayashi,Yoshikazu; Sakamoto,Hirotsugu; Kobayashi,Yasutoshi; Lefor,Alan  Kawarai; Yamamoto,Hironori

doi:10.3892/br.2017.947

Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor‑resistant gastroesophageal reflux disease

Authors:
- Satoshi Shinozaki
- Hiroyuki Osawa
- Yoshikazu Hayashi
- Hirotsugu Sakamoto
- Yasutoshi Kobayashi
- Alan Kawarai Lefor
- Hironori Yamamoto
View Affiliations

Affiliations: Shinozaki Medical Clinic, Utsunomiya 321-3223, Japan, Division of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan, Department of Surgery, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan
Published online on: July 20, 2017 https://doi.org/10.3892/br.2017.947
Pages: 231-235

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastroesophageal reflux disease (GERD) is commonly treated by primary care physicians. Although proton pump inhibitors (PPI) have been the mainstay of GERD treatment for two decades, in some patients GERD is refractory to standard dose PPI for more than eight weeks and is referred to as PPI‑resistant GERD. Vonoprazan, a novel competitive acid blocker, became available in Japan for the treatment of patients with GERD, and has greater acid inhibition than existing PPIs. The aim of the present study was to determine the effect of vonoprazan 10 mg daily on PPI‑resistant GERD. We retrospectively reviewed 24 patients with PPI‑resistant GERD treated with vonoprazan 10 mg daily. The Izumo scale was used to evaluate the effect of vonoprazan before and one month after treatment, which reflects quality of life related to gastrointestinal symptoms. The overall rates of improvement and resolution of GERD symptoms were 88% (21/24) and 42% (10/24), respectively, and the score was significantly decreased (before 5.8±1.7, at one month 1.9±1.9, P<0.001). To evaluate the influence of esophageal erosions despite prior PPI treatment, the patients were divided into erosive (n=6) and non-erosive groups (n=18). Vonoprazan achieved 100% (6/6) improvement in the erosive group and 83% (15/18) in the non-erosive group. Patients in the erosive group had a significantly higher rate of resolution than in the non-erosive group [83% (5/6) vs 28% (5/18), P=0.017]. No adverse events occurred. Other GI symptoms in patients with PPI‑resistant GERD were evaluated. The scores for epigastric pain, postprandial distress, constipation and diarrhea were unchanged during the treatment period. In conclusion, vonoprazan 10 mg daily is effective for the treatment of patients with PPI‑resistant GERD. Vonoprazan resolves GERD symptoms in patients with erosions more than in those without erosions. This is the first report on the effect of vonoprazan 10 mg on PPI‑resistant GERD.

View Figures

View References

1	Dimenäs E: Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl. 199:18–21. 1993. View Article : Google Scholar : PubMed/NCBI
2	Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, et al: Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 51:751–767. 2016. View Article : Google Scholar : PubMed/NCBI
3	Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S and Hibi T: Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 1:175–183. 2013. View Article : Google Scholar : PubMed/NCBI
4	Toghanian S, Johnson DA, Stålhammar NO and Zerbib F: Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey. Clin Drug Investig. 31:703–715. 2011. View Article : Google Scholar : PubMed/NCBI
5	Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther. 42:719–730. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shinozaki S, Nomoto H, Kondo Y, Sakamoto H, Hayashi Y, Yamamoto H, Lefor AK and Osawa H: Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 32:255–260. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, et al: Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 95:156–161. 2017. View Article : Google Scholar : PubMed/NCBI
8	Kakuta E, Yamashita N, Katsube T, Kushiyama Y, Suetsugu H, Furuta K and Kinoshita Y: Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med. 50:1517–1522. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kimura K and Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1:87–97. 1969. View Article : Google Scholar
10	Shinozaki S, Osawa H, Sakamoto H, Hayashi Y, Lefor A Kawarai and Yamamoto H: The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 63:230–235. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yoshioka T, Okimoto N, Okamoto K and Sakai A: A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. J Bone Miner Metab. 31:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
12	Okimoto E, Ishimura N, Morito Y, Mikami H, Shimura S, Uno G, Tamagawa Y, Aimi M, Oshima N, Kawashima K, et al: Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community. J Gastroenterol Hepatol. 30:1140–1146. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kinoshita Y and Chiba T: FUTURE study group: Therapeutic effects of famotidine on chronic symptomatic gastritis: Subgroup analysis from FUTURE study. J Gastroenterol. 47:377–386. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kinoshita Y and Chiba T: FUTURE study group: Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: Based on the large-scale survey, FUTURE study. Intern Med. 50:2269–2276. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tack J and Fass R: Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 19. Suppl 1:28–34. 2004. View Article : Google Scholar
16	Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, et al: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 43:1048–1059. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kinoshita Y and Hongo M: Japan TWICE study group: Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: The Japan-based TWICE study. Am J Gastroenterol. 107:522–530. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H and Ikeuchi S: RPZ Study Group: Therapeutic response to twice-daily Rabeprazole on health-related quality of life and symptoms in patients with refractory reflux esophagitis: A multicenter observational study. Intern Med. 56:1131–1139. 2017. View Article : Google Scholar : PubMed/NCBI
19	Fackler WK, Ours TM, Vaezi MF and Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 122:625–632. 2002. View Article : Google Scholar : PubMed/NCBI